Dr Reddy's Wins Higher Target As HSBC Backs Its Global Expansion Strategy - Details Inside

HSBC has raised its FY27-28 earnings per share estimates by 2.8% to 4.6%, reflecting a more optimistic outlook for semaglutide and abatacept.